Literature DB >> 24553860

Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases.

Annalisa Bramati1, Serena Girelli, Gabriella Farina, Maria Chiara Dazzani, Valter Torri, Anna Moretti, Sheila Piva, Mariastella Dimaiuta, Nicla La Verde.   

Abstract

The aim of our study was to investigate the occurrence of osteonecrosis of the jaw (ONJ) after implementation of dental preventive measures before starting bisphosphonates (BPs) therapy and during treatment. All consecutive patients with bone lesions eligible for BPs treatment were prospectively evaluated. Before starting BPs, each patient underwent a strict dental preventive program with a specialized odontoiatric team. The odontoiatric evaluation identified patients with oral pathologies or inadequate oral hygiene and provided a dental preventive treatment. From April 2007 to April 2012, 254 patients were enrolled. After excluding patients due to previous BPs treatment, 212 patients with a mean age of 74 years (range 37-95) were included. On average, patients received 9.7 treatment cycles (range 1-48). No ONJ was recorded (0.0 %; 95 % confidence interval [CI] 0.0-1.4). Comparing this risk with that observed in a previous cohort who did not receive dental prevention (16/186, 8.6 %; 95 % CI 4.2-15.3 %), we observed clear efficacy in preventing ONJ (relative risk reduction: 100 %, 95 % CI 86-100 %, P < 0.0001). We developed a strict three-step prevention program that is able to decrease ONJ incidence and the need for destructive surgery with permanent sequelae. We demonstrated that ONJ could be effectively prevented. We recommend a mandatory preventive program involving a multidisciplinary team for all patients starting BPs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24553860     DOI: 10.1007/s00774-014-0566-x

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  26 in total

Review 1.  Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases.

Authors:  O Filleul; E Crompot; S Saussez
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-28       Impact factor: 4.553

2.  Osteonecrosis of the jaw and bisphosphonates.

Authors:  Brian G M Durie; Michael Katz; John Crowley
Journal:  N Engl J Med       Date:  2005-07-07       Impact factor: 91.245

3.  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; Leon A Assael; Regina Landesberg; Robert E Marx; Bhoomi Mehrotra
Journal:  J Oral Maxillofac Surg       Date:  2009-05       Impact factor: 1.895

4.  American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.

Authors:  Catherine H Van Poznak; Sarah Temin; Gary C Yee; Nora A Janjan; William E Barlow; J Sybil Biermann; Linda D Bosserman; Cindy Geoghegan; Bruce E Hillner; Richard L Theriault; Dan S Zuckerman; Jamie H Von Roenn
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

5.  Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate.

Authors:  C W Löwik; G van der Pluijm; L J van der Wee-Pals; H B van Treslong-De Groot; O L Bijvoet
Journal:  J Bone Miner Res       Date:  1988-04       Impact factor: 6.741

6.  Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.

Authors:  Lee S Rosen; David Gordon; N Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; Maciej Krzakowski; Marek Pawlicki; Paul De Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John Seaman
Journal:  Cancer       Date:  2004-06-15       Impact factor: 6.860

7.  Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.

Authors:  M A Dimopoulos; E Kastritis; C Bamia; I Melakopoulos; D Gika; M Roussou; M Migkou; E Eleftherakis-Papaiakovou; D Christoulas; E Terpos; A Bamias
Journal:  Ann Oncol       Date:  2008-08-09       Impact factor: 32.976

Review 8.  Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.

Authors:  Matthias Troeltzsch; Timothy Woodlock; Stefanie Kriegelstein; Timm Steiner; Karl Messlinger; Markus Troeltzsch
Journal:  J Can Dent Assoc       Date:  2012       Impact factor: 1.316

9.  Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.

Authors:  P M Boonekamp; L J van der Wee-Pals; M M van Wijk-van Lennep; C W Thesing; O L Bijvoet
Journal:  Bone Miner       Date:  1986-02

10.  Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

Authors:  C I Ripamonti; M Maniezzo; T Campa; E Fagnoni; C Brunelli; G Saibene; C Bareggi; L Ascani; E Cislaghi
Journal:  Ann Oncol       Date:  2008-07-22       Impact factor: 32.976

View more
  12 in total

1.  The Prevention of Medication-related Osteonecrosis of the Jaw.

Authors:  Philipp Poxleitner; Monika Engelhardt; Rainer Schmelzeisen; Pit Voss
Journal:  Dtsch Arztebl Int       Date:  2017-02-03       Impact factor: 5.594

Review 2.  Interventions for managing medication-related osteonecrosis of the jaw.

Authors:  Natalie H Beth-Tasdogan; Benjamin Mayer; Heba Hussein; Oliver Zolk; Jens-Uwe Peter
Journal:  Cochrane Database Syst Rev       Date:  2022-07-12

Review 3.  Medication-Related Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular Therapeutic Approaches.

Authors:  Thomas Lombard; Virginie Neirinckx; Bernard Rogister; Yves Gilon; Sabine Wislet
Journal:  Stem Cells Int       Date:  2016-09-18       Impact factor: 5.443

4.  Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India.

Authors:  Pramod S Sankar; S A Thilak; P Nayak; J P Tripathy; B Satheesan; A V Rajitha
Journal:  Contemp Clin Dent       Date:  2018 Jan-Mar

5.  Awareness among patient at risk of developing Medication Related Osteonecrosis of the Jaw (MRONJ) - A primary prevention strategy.

Authors:  Abdulrhman Al Abdullateef; Muhanad S Alhareky
Journal:  Saudi Pharm J       Date:  2020-05-15       Impact factor: 4.330

6.  Osteonecrosis of the Jaw Beyond Bisphosphonates: Are There Any Unknown Local Risk Factors?

Authors:  Johann Lechner; Volker von Baehr; Bernd Zimmermann
Journal:  Clin Cosmet Investig Dent       Date:  2021-01-19

7.  Antiresorptive medication in oncology: the clinical and dental profile of patients in a reference center.

Authors:  Vitor Hugo Candido Ferreira; Aristilia Tahara Kemp; Joana Vendruscolo; Laurindo Moacir Sassi; Juliana Lucena Schussel
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2021-02-28

Review 8.  Interventions for managing medication-related osteonecrosis of the jaw.

Authors:  Natalie H Beth-Tasdogan; Benjamin Mayer; Heba Hussein; Oliver Zolk
Journal:  Cochrane Database Syst Rev       Date:  2017-10-06

Review 9.  The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention.

Authors:  Olga Di Fede; Vera Panzarella; Rodolfo Mauceri; Vittorio Fusco; Alberto Bedogni; Lorenzo Lo Muzio; Giuseppina Campisi
Journal:  Biomed Res Int       Date:  2018-09-16       Impact factor: 3.411

Review 10.  Dental care for patients taking antiresorptive drugs: a literature review.

Authors:  Minju Song
Journal:  Restor Dent Endod       Date:  2019-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.